AZD6482 + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Antiplatelet Effect
Conditions
Antiplatelet Effect
Trial Timeline
Jan 1, 2008 → May 1, 2008
NCT ID
NCT00688714About AZD6482 + Placebo
AZD6482 + Placebo is a phase 1 stage product being developed by AstraZeneca for Antiplatelet Effect. The current trial status is completed. This product is registered under clinical trial identifier NCT00688714. Target conditions include Antiplatelet Effect.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00688714 | Phase 1 | Completed |
Competing Products
1 competing product in Antiplatelet Effect
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD6482 + Clopidogrel + ASA | AstraZeneca | Phase 1 | 33 |